Bio-Path Holdings, Inc., (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr. Ana Maria Tari, PhD, MBA has been appointed Director, Preclinical Operations and Research. She will report to Peter Nielsen, President and Chief Executive Officer and be responsible for leading the Company’s evaluation and selection of new drug targets for licensing and development; design, source and direct preclinical in vitro and in vivo studies; and be the primary scientific liaison to the scientific community and clinical trial sites, including University of Texas M. D. Anderson Cancer Center.
Dr. Tari was a key member of the research team that performed the basic research and preclinical development of the liposomal delivery technology that Bio-Path has licensed from The University of Texas M. D. Anderson Cancer Center and is at the core of the Company’s research and development efforts. In particular, Dr. Tari was the lead researcher who developed the Company’s lead product candidate Liposomal Grb-2 (BP-100-1.01) that is currently in a Phase I clinical trial in blood cancers. Dr. Tari has authored or co-authored numerous articles in leading scientific journals, including several on the research done in Liposomal Grb-2. Previously, Dr. Tari has performed consulting work for the Company, being particularly instrumental in the transfer of licensed technology to the Company including manufacturing techniques, drug assays and testing methods.
Peter Nielsen, President and Chief Executive Officer of Bio-Path commented, “We are very fortunate to have Ana Tari join Bio-Path. Ana is a leader in the field of liposomal antisense therapeutics and will prove to be an invaluable resource as we develop and commercialize our proprietary neutral lipid delivery technology of which Ana was instrumental in developing. I look forward to working with Ana as we continue to advance our technology in our current clinical trial and her experience in the identification of new drug candidates and clinical trial design will be instrumental when we seek to expand into new drug targets.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV